WO2004013298A3 - 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections - Google Patents

2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections Download PDF

Info

Publication number
WO2004013298A3
WO2004013298A3 PCT/US2003/024288 US0324288W WO2004013298A3 WO 2004013298 A3 WO2004013298 A3 WO 2004013298A3 US 0324288 W US0324288 W US 0324288W WO 2004013298 A3 WO2004013298 A3 WO 2004013298A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
infections
flavivitridae
dideoxynucleoside
Prior art date
Application number
PCT/US2003/024288
Other languages
French (fr)
Other versions
WO2004013298A2 (en
Inventor
Junxing Shi
Raymond F Schinazi
Robert Striker
Original Assignee
Pharmasset Ltd
Univ Emory
Univ Leland Stanford Junior
Junxing Shi
Raymond F Schinazi
Robert Striker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd, Univ Emory, Univ Leland Stanford Junior, Junxing Shi, Raymond F Schinazi, Robert Striker filed Critical Pharmasset Ltd
Priority to AU2003263978A priority Critical patent/AU2003263978A1/en
Publication of WO2004013298A2 publication Critical patent/WO2004013298A2/en
Publication of WO2004013298A3 publication Critical patent/WO2004013298A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Abstract

A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a R-L- or (3-D-2',3'-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
PCT/US2003/024288 2002-08-01 2003-08-01 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections WO2004013298A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003263978A AU2003263978A1 (en) 2002-08-01 2003-08-01 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45371502P 2002-08-01 2002-08-01
US60/453,715 2002-08-01

Publications (2)

Publication Number Publication Date
WO2004013298A2 WO2004013298A2 (en) 2004-02-12
WO2004013298A3 true WO2004013298A3 (en) 2004-04-01

Family

ID=31496097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024288 WO2004013298A2 (en) 2002-08-01 2003-08-01 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections

Country Status (2)

Country Link
AU (1) AU2003263978A1 (en)
WO (1) WO2004013298A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101277950B (en) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 Inhibitors of serine proteases
CN101437534A (en) 2006-03-08 2009-05-20 半球生物制药公司 Broad spectrum immune and antiviral gene modulation by oral interferon
US8075877B2 (en) 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
PT2794629T (en) * 2011-12-20 2017-07-20 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019363A1 (en) * 2000-02-18 2002-02-14 Ismaili Hicham Moulay Alaoui Method for the treatment or prevention of flavivirus infections using nucleoside analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019363A1 (en) * 2000-02-18 2002-02-14 Ismaili Hicham Moulay Alaoui Method for the treatment or prevention of flavivirus infections using nucleoside analogues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C

Also Published As

Publication number Publication date
WO2004013298A2 (en) 2004-02-12
AU2003263978A1 (en) 2004-02-23
AU2003263978A8 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
WO2001060315A3 (en) Method for the treatment or prevention of flavivirus infections using nucleoside analogues
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
WO2001091737A3 (en) Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
WO2001092282A3 (en) Methods and compositions for treating flaviviruses and pestiviruses
WO2006130553A3 (en) Hcv protease inhibitors
WO2001096353A3 (en) 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES
WO2003053349A3 (en) Inhibitors of hepatitis c virus
WO2004046159A8 (en) Antiviral nucleoside derivatives
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
WO2003053360A3 (en) Treatment of ebv and khsv infection and associated abnormal cellular proliferation
WO2001072294A3 (en) Method of treating hepatitis delta viral infection
WO2004013298A3 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
ZA991029B (en) Composition and methods for treatment of hiv infections.
WO2005063225A8 (en) Compositions and methods for treating hepatitis c virus (hcv) infection
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
WO2004006848A3 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
WO2004094991A3 (en) Treatment or prevention of respiratory viral infections with alpha thymosin peptides
WO2002006343A3 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
WO2002078717A3 (en) Compositions and methods for reducing rna virus pathogenicity
RU2003117557A (en) METHOD FOR PREVENTING COMPLICATIONS OF HERPES-VIRAL INFECTION IN CORNERAL DAMAGES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP